COST-EFFECTIVENESS OF LIRAGLUTIDE FOR SUBJECTS WITH TYPE 2 DIABETES IN SPAIN

被引：0
|
作者：
Ramirz de Arellano, A. [1 ]
Hunt, B. [2 ]
Mezquita Raya, P. [3 ]
Briones, T. [1 ]
Perez, A. [1 ,4 ]
Valentine, W. J. [2 ]
机构：
[1] Novo Nordisk Pharma SA, Madrid, Spain
[2] Ossian Hlth Econ & Commun, Basel, Switzerland
[3] Hosp Torrecardenas, Clin San Pedro, Almeria, Spain
[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB69
引用
收藏
页码：A249 / A250
页数：2
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN THE UK
    Schlueter, M.
    Vega-Hernandez, G.
    Wojcik, R.
    VALUE IN HEALTH, 2016, 19 (07) : A675 - A675
  • [22] The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
    Lars Holger Ehlers
    Mark Lamotte
    Sofia Monteiro
    Susanne Sandgaard
    Pia Holmgaard
    Evan C. Frary
    Niels Ejskjaer
    Diabetes Therapy, 2021, 12 : 1523 - 1534
  • [23] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE-2 DIABETES MELLITUS IN SPAIN
    Capel, M.
    Pomares, E.
    Perez-Alcantara, F.
    Simon, S.
    VALUE IN HEALTH, 2020, 23 : S508 - S508
  • [24] Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain
    Pinol, Carme
    Roze, Stephane
    Valentine, William
    Evers, Thomas
    GACETA SANITARIA, 2007, 21 (02) : 97 - 104
  • [25] The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30kg/m2
    Dilla, Tatiana
    Alexiou, Dimitra
    Chatzitheofilou, Ismini
    Ayyub, Ruba
    Lowin, Julia
    Norrbacka, Kirsi
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (05) : 443 - 452
  • [26] COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS INSULIN GLARGINE AND LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Bargiota, A.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [27] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN COMPARED WITH LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH METFORMIN AND SULFONYLUREA IN FRANCE
    Troelsgaard, A.
    Pitcher, A.
    Granados, D.
    Hemels, M.
    Lloyd, A.
    VALUE IN HEALTH, 2014, 17 (07) : A346 - A347
  • [28] The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes
    Menon, Kirthi
    de Courten, Barbora
    Magliano, Dianna J.
    Ademi, Zanfina
    Liew, Danny
    Zomer, Ella
    NUTRIENTS, 2022, 14 (01)
  • [29] Cost-effectiveness of primary prevention of type 2 diabetes
    Icks, A.
    Chernyak, N.
    Klein, A.
    Brinks, R.
    Genz, J.
    Giani, G.
    DIABETOLOGE, 2011, 7 (02): : 92 - 98
  • [30] Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain
    Mezquita-Raya, Pedro
    Ramirez de Arellano, Antonio
    Kragh, Nana
    Vega-Hernandez, Gabriela
    Pohlmann, Johannes
    Valentine, William J.
    Hunt, Barnaby
    DIABETES THERAPY, 2017, 8 (02) : 401 - 415
12345